Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed AL Amyloidosis: Experience of Two Centers in Canada

被引：1
|
作者：
Alahwal, Hatem [1 ]
Song, Kevin W. [2 ]
Duggan, Peter [3 ]
Sutherland, Heather J. [4 ]
Neri, Paola [5 ]
Broady, Raewyn [6 ]
Bahlis, Nizar J. [5 ,7 ]
Jimenez-Zepeda, Victor [3 ]
机构：
[1] British Columbia Canc Agcy, Vancouver, BC, Canada
[2] Univ British Columbia, Div Hematol & Leukemia, BMT Program BC, Vancouver, BC, Canada
[3] Tom Baker Canc Clin, Dept Med Oncol & Hematol, Calgary, AB, Canada
[4] BCCA, Vancouver, BC, Canada
[5] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[6] Univ British Columbia, Div Hematol, Leukemia BMT Program BC, Vancouver, BC, Canada
[7] Univ Calgary, Calgary, AB, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2131.2131
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2131
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Retrospective Comparison of Bortezomib-containing Regimens with Vincristine-Doxorubicin-Dexamethasone (VAD) as Induction Treatment Prior to Autologous Stem Cell Transplantation for Multiple Myeloma
    Eom, Hyeon-Seok
    Min, Chang-Ki
    Cho, Byung-Sik
    Lee, Seok
    Lee, Jong-Wook
    Min, Woo-Sung
    Kim, Chun-Choo
    Kim, Myungshin
    Kim, Yonggoo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (07) : 449 - 455
  • [42] Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients
    Shah, Gunjan
    Kaul, Esha
    Fallo, Shelly
    Cossor, Furha
    Smith, Hedy
    Sprague, Kellie
    Klein, Andreas
    Miller, Kenneth
    Comenzo, Raymond
    CLINICAL THERAPEUTICS, 2013, 35 (10) : 1614 - 1620
  • [43] (Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials
    Anyou Wang
    Qiaohong Duan
    Xin Liu
    Kaiyang Ding
    Yongsheng Han
    Weibo Zhu
    Xiaoyan Cai
    Jingsheng Wu
    Zimin Sun
    Annals of Hematology, 2012, 91 : 1779 - 1784
  • [44] (Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials
    Wang, Anyou
    Duan, Qiaohong
    Liu, Xin
    Ding, Kaiyang
    Han, Yongsheng
    Zhu, Weibo
    Cai, Xiaoyan
    Wu, Jingsheng
    Sun, Zimin
    ANNALS OF HEMATOLOGY, 2012, 91 (11) : 1779 - 1784
  • [45] Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients.
    Cornell, Robert F.
    Hari, Parameswaran
    Goodman, Stacey
    Costa, Luciano J.
    Fraser, Raphael
    Estrada-Merly, Noel
    Kumar, Shaji
    Qazilbash, Muzaffar H.
    D'Souza, Anita
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
    Magarotto, Valeria
    Bringhen, Sara
    Offidani, Massimo
    Benevolo, Giulia
    Patriarca, Francesca
    Mina, Roberto
    Falcone, Antonietta Pia
    De Paoli, Lorenzo
    Pietrantuono, Giuseppe
    Gentili, Silvia
    Musolino, Caterina
    Giuliani, Nicola
    Bernardini, Annalisa
    Conticello, Concetta
    Pulini, Stefano
    Ciccone, Giovannino
    Maisnar, Vladimir
    Ruggeri, Marina
    Zambello, Renato
    Guglielmelli, Tommasina
    Ledda, Antonio
    Liberati, Anna Marina
    Montefusco, Vittorio
    Hajek, Roman
    Boccadoro, Mario
    Palumbo, Antonio
    BLOOD, 2016, 127 (09) : 1102 - 1108
  • [47] Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database
    Jimenez-Zepeda, Victor
    Reece, Donna E.
    Arleigh, McCurdy R.
    Masih-Khan, Esther
    Atenafu, Eshetu G.
    Sebag, Michael
    Stakiw, Julie
    Song, Kevin
    Leblanc, Richard
    Reiman, Tony
    Louzada, Martha L.
    Kotb, Rami
    Gul, Engin
    Venner, Christopher P.
    BLOOD, 2018, 132
  • [48] Real-life experience with bortezomib-based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: a Polish retrospective multicenter study
    Hus, Iwona
    Walter-Croneck, Adam
    Masternak, Anna
    Jurczyszyn, Artur
    Usnarska-Zubkiewicz, Lidia
    Bolkun, Lukasz
    Druzd-Sitek, Agnieszka
    Rymko, Marcin
    Letowska, Jadwiga
    Lech-Maranda, Ewa
    Pasiarski, Marcin
    Dmoszynska, Anna
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2017, 127 (11): : 765 - 774
  • [49] BETTER OUTCOME IN AL AMYLOIDOSIS (ALA) TREATED WITH MULTIPLE MYELOMA-ORIENTED REGIMENS COMPARED WITH CYCLOPHOSPHAMIDE/ BORTEZOMIB/DEXAMETHASONE (CYBORD) IN A SINGLE CENTER EXPERIENCE
    Belotti, A.
    Ribolla, R.
    Crippa, C.
    Orlando, V.
    D'Adda, M.
    Re, A.
    Morello, E.
    Cattaneo, C.
    Rossi, G.
    HAEMATOLOGICA, 2016, 101 : 545 - 545
  • [50] Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study
    Bellofiore, Claudia
    Basset, Marco
    Sanna, Giuseppe Damiano
    Foli, Andrea
    Mussinelli, Roberta
    Nanci, Martina
    Fogliani, Alessandro
    Ciardo, Martina
    Nuvolone, Mario
    Merlini, Giampaolo
    Palladini, Giovanni
    Milani, Paolo
    HEMASPHERE, 2025, 9 (03):
12345